Global Fetal and Neonatal Heart Monitor Market Size was USD 2.40 Billion in 2025, this report covers Market growth, trend, opportunity and forecast from 2026-2032

The Fetal and Neonatal Heart Monitor market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.

1. GE HealthCare Technologies Inc.:

   GE HealthCare Technologies Inc. holds a leading position in the fetal and neonatal heart monitor market, leveraging its extensive installed base in hospitals, integrated perinatal care platforms, and strong brand trust among obstetricians and neonatologists. The company offers comprehensive fetal monitoring systems that integrate cardiotocography, fetal ECG, and maternal vital sign monitoring into unified workflows, which is particularly attractive for tertiary care centers and integrated delivery networks. Its presence in both developed and emerging markets ensures that GE equipment is frequently specified in public tenders and private hospital expansion projects focused on maternal and neonatal care.

   In 2025, GE HealthCare’s fetal and neonatal heart monitoring business is estimated to generate revenue of USD 480.00 million , corresponding to a market share of approximately 20.00% of the global fetal and neonatal heart monitor market, based on a total market size of USD 2.40 Billion as reported by ReportMines. This revenue scale indicates that GE operates as a tier-one vendor with strong pricing power, robust service contracts, and significant influence over clinical purchasing committees. The company’s market share demonstrates that it competes aggressively at the high end of the market while defending share in mid-acuity segments through flexible configurations.

   Strategically, GE differentiates itself through advanced imaging and monitoring integration, leveraging its strengths in ultrasound and perinatal IT to create interoperable ecosystems. Its cardiology and maternal-fetal medicine software suites support decision support tools, automated trend analysis, and remote data access, which are increasingly critical for high-risk pregnancy management and neonatal intensive care units. The company’s global service network, training programs, and ability to bundle fetal and neonatal heart monitors with other capital equipment provide additional competitive advantages when negotiating large framework agreements.

   GE is also investing in connectivity, telehealth, and AI-enabled analytics for fetal heart rate interpretation, which aligns with hospital digital transformation initiatives. By embedding predictive algorithms and alarm management tools into its perinatal monitoring platforms, GE aims to reduce clinical workload and support earlier detection of fetal distress and neonatal hemodynamic compromise. These capabilities reinforce its premium positioning and help justify higher average selling prices relative to regional competitors.

2. Koninklijke Philips N.V.:

   Koninklijke Philips N.V. is a core global competitor in the fetal and neonatal heart monitor market, with a strong heritage in patient monitoring and perinatal care solutions. The company’s fetal and neonatal portfolio is deeply integrated into its broader hospital monitoring ecosystem, enabling continuous data flow from delivery rooms and neonatal intensive care units into centralized command centers and electronic medical records. This end-to-end integration positions Philips as a preferred vendor for health systems seeking standardized monitoring platforms across maternal, neonatal, and adult care.

   For 2025, Philips’ fetal and neonatal heart monitoring business is estimated to achieve revenue of USD 420.00 million , representing a market share of about 17.50% . This scale underscores Philips as a top-tier player, slightly behind the market leader but with strong penetration in Europe, North America, and parts of Asia-Pacific. The company’s share reflects its ability to compete effectively on innovation, user experience, and connectivity, rather than only on price, which is important in high-acuity maternity and neonatal settings.

   Philips differentiates itself through ergonomic monitor design, intuitive user interfaces, and robust interoperability with hospital IT infrastructure. Its fetal and neonatal heart monitors often feature advanced signal processing for noisy delivery environments, highly configurable alarm limits, and seamless wired and wireless networking. These attributes support workflow efficiency for labor and delivery clinicians and NICU nurses, particularly in high-throughput hospitals.

   The company is heavily focused on digital health, offering cloud-based data management, remote viewing applications, and analytics that help clinicians track fetal heart rate patterns and neonatal cardiovascular stability over time. By coupling monitoring hardware with software-driven services, Philips can pursue recurring revenue models and long-term service contracts. This strategy strengthens customer stickiness, reduces switching risk, and allows Philips to capture value from the market’s 7.20% CAGR growth profile through both new installations and software upgrades.

3. Siemens Healthineers AG:

   Siemens Healthineers AG participates in the fetal and neonatal heart monitor market primarily through its broader patient monitoring and hospital IT solutions, often targeting large healthcare networks and university hospitals. While it is better known for imaging and diagnostic technologies, Siemens leverages these relationships to cross-sell monitoring systems into perinatal departments, emphasizing interoperability and data integration across the care continuum from prenatal diagnostics to neonatal intensive care. This positioning is particularly strong in Europe and selected emerging markets where public hospitals prioritize integrated platforms.

   In 2025, Siemens Healthineers’ fetal and neonatal heart monitoring segment is estimated to generate revenue of USD 240.00 million , corresponding to a market share of roughly 10.00% . These figures indicate a solid, mid-teens position among global competitors, with the company acting as a strategic alternative to the top two leaders. Its market share signals that Siemens is competitive in large, system-wide bids, even if it is less focused on stand-alone fetal monitor sales compared with more specialized vendors.

   Siemens’ key advantages include its strong expertise in health IT, data analytics, and enterprise-wide connectivity. The company focuses on integrating fetal and neonatal heart data with laboratory results, imaging findings, and maternal risk profiles to support more holistic clinical decision-making. This approach aligns with the growing emphasis on precision obstetrics and neonatal care pathways, where risk stratification and longitudinal monitoring are essential for improving outcomes.

   From a competitive differentiation standpoint, Siemens emphasizes cybersecurity, system reliability, and service quality, which are critical for high-dependency environments such as NICUs. Its capability to integrate fetal and neonatal heart monitors into existing hospital infrastructure, along with remote diagnostics and predictive maintenance, reduces downtime and total cost of ownership. These strengths make Siemens particularly attractive for long-term strategic partnerships with health systems undergoing digital transformation initiatives.

4. Natus Medical Incorporated:

   Natus Medical Incorporated is a highly specialized player in neonatal and pediatric care, with a strong reputation in neurodiagnostics and NICU monitoring. In the fetal and neonatal heart monitor market, Natus focuses more on neonatal cardiac monitoring within intensive care units, emphasizing high sensitivity, small-patient sensor design, and compatibility with incubators and warmers. Its products are widely used in neonatal intensive care environments where precise heart rate and rhythm monitoring for premature and critically ill infants is essential.

   For 2025, Natus’ fetal and neonatal heart monitoring-related business is estimated to produce revenue of USD 180.00 million , equating to a market share of around 7.50% . This market share underscores Natus as a focused, mid-sized competitor, particularly strong in North American and European NICUs. Despite not matching the volume of the largest conglomerates, its specialization enables premium pricing and strong clinician loyalty in neonatal cardiology and neurocritical care segments.

   Natus differentiates itself through deep clinical specialization, with devices tailored for very low birth weight infants and complex congenital heart conditions. Its monitoring solutions often integrate with neonatal neuro-monitoring systems, allowing combined assessment of cardiac and neurological status. This integration aligns with the needs of advanced NICUs managing hypoxic-ischemic encephalopathy and other multi-system complications, where synchronized monitoring improves clinical decision-making.

   The company’s strategic advantage also lies in its educational programs, research collaborations with leading children’s hospitals, and support for clinical studies in neonatal cardiology. By co-developing protocols and usability features with frontline clinicians, Natus maintains strong brand equity in high-acuity neonatal settings. For investors and strategic planners, this niche focus provides resilience and defensibility, even as broader market growth is driven by increased institutional births and NICU capacity expansions globally.

5. Drägerwerk AG & Co. KGaA:

   Drägerwerk AG & Co. KGaA is a key player in neonatal care, especially known for incubators, ventilators, and comprehensive NICU solutions. In the fetal and neonatal heart monitor market, Dräger leverages its strong footprint in neonatal intensive care to offer integrated monitoring systems that combine heart rate, oxygenation, and respiratory parameters. This integrated approach is particularly appealing to hospitals seeking to standardize equipment across NICUs and minimize vendor fragmentation.

   In 2025, Dräger’s fetal and neonatal heart monitoring business is estimated to reach revenue of USD 180.00 million , corresponding to a market share of approximately 7.50% . This performance places Dräger among the solid mid-tier competitors, with strong share in Europe, the Middle East, and parts of Asia. The company’s presence in public tenders for neonatal equipment bundles often allows it to capture monitoring placements when hospitals upgrade incubators and respiratory support systems.

   Dräger’s competitive advantage lies in its system-level approach to neonatal care. Its monitors are designed to integrate seamlessly with incubators and ventilators, minimizing cable clutter and enabling consistent workflows for NICU nurses. The company emphasizes gentle care principles, such as minimizing noise and light exposure, while still providing high-fidelity cardiac monitoring for fragile preterm infants.

   From a strategic standpoint, Dräger focuses on durable, reliable hardware and strong after-sales service rather than rapid product churn. Its long product life cycles and comprehensive training support help hospitals manage total cost of ownership, an important consideration for budget-constrained public health systems. As NICU capacity expands in emerging markets, Dräger’s reputation for robust neonatal care ecosystems provides an avenue to capture incremental market share in heart monitoring as part of broader equipment packages.

6. Fukuda Denshi Co., Ltd.:

   Fukuda Denshi Co., Ltd. is a significant regional player in Asia, particularly in Japan and other parts of East Asia, with a strong presence in cardiology and patient monitoring. In the fetal and neonatal heart monitor market, the company focuses on compact, reliable monitors suitable for both hospital and clinic use, catering to obstetric practices, maternity hospitals, and smaller NICUs. Its products are often valued for reliability, cost-effectiveness, and adherence to local clinical practice preferences.

   For 2025, Fukuda Denshi’s fetal and neonatal heart monitoring revenue is estimated at USD 120.00 million , representing a market share of roughly 5.00% . This market share position reflects a strong regional footprint, particularly in Japan, but more limited penetration in North America and Western Europe. The company competes effectively in tender-driven markets and mid-acuity segments where price-performance balance is a critical factor.

   Fukuda Denshi’s strategic edge comes from its expertise in electrocardiography and long-standing relationships with cardiology and obstetrics departments in Japan. Its fetal heart monitors and neonatal ECG systems benefit from robust signal processing algorithms, which provide stable readings even in busy labor wards. The company’s familiarity with local regulatory requirements and reimbursement structures also enables it to respond quickly to evolving clinical guidelines in its core markets.

   Looking forward, Fukuda Denshi can capitalize on rising birth volumes and NICU infrastructure upgrades across Asia by offering scalable product ranges that serve both tertiary hospitals and community maternity centers. Integrating connectivity features and cloud-based data sharing into its fetal and neonatal heart monitors will be critical to maintaining competitiveness as health systems in Asia pursue digital transformation and tele-perinatal care models.

7. OSYPKA Medical GmbH:

   OSYPKA Medical GmbH is a specialized medical device company with a strong focus on cardiac monitoring and pacing technologies. In the fetal and neonatal heart monitor market, it plays a niche but important role, particularly in high-acuity neonatal cardiac care and specialized obstetric monitoring environments. Its product portfolio typically targets institutions that require advanced cardiac signal analysis and are managing complex fetal and neonatal cardiovascular conditions.

   In 2025, OSYPKA Medical’s revenue from fetal and neonatal heart monitoring is estimated at USD 60.00 million , corresponding to a market share of around 2.50% . This relatively modest share reflects its status as a niche player focusing on specialized segments rather than broad volume-based competition. Nonetheless, within its subsegment, OSYPKA can command premium pricing and maintain strong clinician loyalty due to its specialized features and focus on cardiac performance.

   OSYPKA differentiates itself through advanced arrhythmia detection, high-resolution ECG capabilities, and tailoring of systems for very small patients, including preterm neonates with complex hemodynamic instability. Its monitors are often used in specialized NICUs and pediatric cardiac centers where fine-grained heart rate variability and rhythm analysis are clinically relevant. This focus aligns with tertiary and quaternary care institutions managing congenital heart disease and post-surgical neonatal patients.

   Strategically, OSYPKA’s small size allows it to innovate quickly and collaborate closely with leading clinicians to refine product capabilities. Its challenge, and opportunity, lies in expanding distribution networks and integrating its systems with broader hospital IT platforms, which could improve adoption as hospitals move toward standardized digital ecosystems. Partnerships or OEM agreements with larger monitoring companies could be a path for increased scale within the steadily growing fetal and neonatal heart monitor market.

8. Mindray Medical International Limited:

   Mindray Medical International Limited is a major global competitor originating from China, with strong momentum in patient monitoring, anesthesia, and ultrasound systems. In the fetal and neonatal heart monitor market, Mindray has leveraged its cost-competitive manufacturing and expanding R&D capabilities to offer a broad range of fetal monitors, cardiotocography systems, and neonatal bedside monitors. Its value proposition resonates strongly with emerging markets and cost-sensitive private hospitals seeking reliable technology at accessible price points.

   Mindray’s 2025 revenue from fetal and neonatal heart monitoring is estimated at USD 180.00 million , giving it an approximate market share of 7.50% . These figures highlight Mindray as an ascending mid-tier global player, particularly strong in Asia-Pacific, Latin America, and parts of Eastern Europe. The company’s share gains in recent years have often come at the expense of legacy vendors in competitive tenders, due to attractive pricing and improving product sophistication.

   Mindray’s strategic advantage lies in its ability to localize products, maintain competitive pricing, and still invest in features such as high-quality displays, multi-parameter monitoring, and connectivity with hospital networks. Its fetal and neonatal heart monitors frequently offer configurability that allows institutions to standardize on one platform across different acuity levels, which can simplify training and maintenance. This approach is particularly relevant for fast-growing private hospital chains in emerging economies.

   The company is investing in international regulatory approvals, user-centered design, and integration with electronic medical records, which improves its acceptance in more mature markets. As the global fetal and neonatal heart monitor market expands from USD 2.40 Billion in 2025 to USD 3.87 Billion by 2032 at a CAGR of 7.20%, Mindray is well positioned to capture incremental share, especially where budget constraints make premium Western brands less accessible. Continued enhancement of clinical decision support tools and remote monitoring capabilities will be critical to further strengthening its competitive position.

9. Analogic Corporation:

   Analogic Corporation, historically recognized for its strengths in medical imaging and ultrasound technologies, plays a specialized role in the fetal and neonatal heart monitor market through high-performance fetal monitoring and related signal processing technologies. Its expertise in high-end ultrasound and signal acquisition allows it to focus on premium fetal monitoring systems that integrate closely with diagnostic imaging workflows in obstetrics.

   In 2025, Analogic’s estimated revenue from fetal and neonatal heart monitoring is USD 90.00 million , equivalent to a market share of about 3.75% . This share reflects a focused presence, often in institutions that value high-fidelity signal quality and tight integration between fetal monitoring and ultrasound. The company is not a volume leader, but its technologies are often embedded in high-end systems and used by clinicians who manage complex pregnancies.

   Analogic’s competitive differentiation stems from its advanced signal processing, which supports accurate fetal heart rate detection even in challenging clinical environments, such as high maternal BMI or multiple gestations. Its systems often emphasize measurement stability, low artifact rates, and integration with ultrasound imaging to provide synchronized cardiotocography and imaging-based assessments. This combination is valuable in high-risk obstetric centers where detailed assessment of fetal well-being drives clinical decision-making.

   Strategically, the company can capitalize on partnerships and OEM relationships, embedding its fetal heart monitoring technologies into broader platforms or imaging systems from other manufacturers. As perinatal care becomes more data-driven, Analogic’s ability to deliver precise, high-quality cardiac signals will remain a key asset, even as it navigates a market dominated by large multi-modality monitoring vendors.

10. Atom Medical Corporation:

    Atom Medical Corporation is a Japan-based company strongly associated with neonatal care equipment, particularly incubators, infant warmers, and related NICU solutions. In the fetal and neonatal heart monitor market, Atom capitalizes on its NICU presence by offering integrated neonatal monitors designed to work seamlessly with its thermal management devices. This gives the company a distinctive position in neonatal-focused hospitals and maternity centers across Asia and selected global markets.

    Atom Medical’s 2025 revenue from fetal and neonatal heart monitors is estimated at USD 60.00 million , translating into a market share of around 2.50% . This market position underscores Atom as a niche, neonatal-centric player rather than a broad-based monitoring competitor. Its share is concentrated in markets where its incubators and warmers are already well established, allowing cross-selling of compatible cardiac monitoring solutions.

    Atom’s competitive strength lies in designing monitors that fit ergonomically with incubators and minimize disturbance to fragile infants. Its neonatal heart monitors typically emphasize gentle sensor interfaces, low noise alarms, and compact footprints to accommodate crowded NICU environments. These design choices align with best practices in developmental care, which aim to reduce stress and physiological instability in preterm infants.

    From a strategic perspective, Atom can deepen its penetration by offering more comprehensive monitoring bundles with its core neonatal equipment, including modular cardiac monitoring and connectivity solutions that enable centralized NICU surveillance. As NICU infrastructure investment accelerates in fast-growing economies, Atom’s proven neonatal brand and integrated systems position it well to capture incremental sales, provided it continues to invest in connectivity and interoperability with hospital information systems.

11. Medtronic plc:

    Medtronic plc is a global leader in cardiovascular devices and monitoring technologies, with a strong footprint in cardiac rhythm management and hemodynamic monitoring. In the fetal and neonatal heart monitor market, Medtronic’s presence is more specialized, focusing on neonatal and pediatric cardiac monitoring in high-acuity hospital settings rather than routine obstetric fetal monitoring. Its technologies are often employed in pediatric cardiac intensive care units and advanced NICUs managing complex heart disease.

    In 2025, Medtronic’s revenue attributable to fetal and neonatal heart monitoring is estimated at USD 90.00 million , corresponding to a market share of approximately 3.75% . This market share indicates a targeted, specialty-driven presence rather than mainstream dominance across all perinatal monitoring settings. However, within tertiary care centers managing high-risk neonatal cardiac patients, Medtronic’s brand and technology carry substantial weight.

    Medtronic’s strategic advantage is its deep expertise in cardiac electrophysiology, implantable devices, and advanced hemodynamic monitoring. This expertise informs neonatal monitoring solutions that are particularly effective for detecting subtle arrhythmias, conduction abnormalities, and hemodynamic instability in vulnerable infants. Its products can integrate with broader critical care monitoring systems, enabling comprehensive physiological surveillance.

    As neonatal cardiac care becomes more sophisticated, with increasing survival of extremely premature infants and those with complex congenital heart disease, Medtronic can leverage its R&D capabilities to develop even more specialized neonatal monitoring solutions. Partnerships with children’s hospitals and academic centers, along with integration of neonatal cardiac monitoring data into analytics platforms, will help sustain its differentiated niche within the growing fetal and neonatal heart monitor market.

12. Spacelabs Healthcare:

    Spacelabs Healthcare is a well-established provider of patient monitoring and connectivity solutions, with a notable presence in critical care and telemetry. In the fetal and neonatal heart monitor market, Spacelabs extends its expertise in continuous monitoring to labor and delivery units and NICUs, offering systems that integrate fetal heart rate, maternal parameters, and neonatal cardiac monitoring into unified viewing stations. This integrated monitoring capability appeals to hospitals aiming for consistent user interfaces across departments.

    For 2025, Spacelabs Healthcare’s revenue from fetal and neonatal heart monitoring is estimated at USD 90.00 million , giving it an approximate market share of 3.75% . This reflects a solid presence in selected regions, especially in North America and some international markets where Spacelabs has established distribution channels. Its share is driven by hospitals that prioritize interoperability, networked monitoring, and strong technical service support.

    Spacelabs differentiates itself through advanced connectivity, centralized monitoring stations, and flexible configuration options that allow hospitals to tailor monitoring setups for labor suites, postpartum wards, and NICUs. Its systems often feature robust alarm management, real-time waveform viewing, and integration into electronic medical record platforms, which supports streamlined documentation and clinical workflows.

    Strategically, Spacelabs can leverage its strength in enterprise monitoring to deepen penetration in multi-site health systems that value standardized platforms. As hospitals upgrade to more interoperable and cybersecure monitoring infrastructures, Spacelabs’ emphasis on network reliability and IT integration will be a key selling point. Continued investment in fetal heart rate analysis algorithms and neonatal-specific alarm profiles will further enhance its competitiveness against larger diversified vendors.

13. BPL Medical Technologies:

    BPL Medical Technologies is a prominent Indian medical device company with a strong presence in patient monitoring, cardiology equipment, and emergency care systems. In the fetal and neonatal heart monitor market, BPL focuses largely on India and other emerging markets, supplying fetal Dopplers, cardiotocography devices, and neonatal monitors to government hospitals, private maternity centers, and diagnostic clinics. Its value proposition centers on affordability, robustness, and suitability for high-volume, resource-constrained environments.

    In 2025, BPL’s fetal and neonatal heart monitoring revenue is estimated at USD 60.00 million , representing a market share of about 2.50% . While this share is modest on a global scale, BPL holds a substantial share in its core domestic market and plays a critical role in expanding access to fetal and neonatal cardiac monitoring in tier-two and tier-three cities. Its scale in India provides a platform for further regional expansion into South Asia and parts of Africa.

    BPL’s competitive advantage lies in its deep understanding of local clinical workflows, price-sensitive procurement practices, and challenging operating environments where power reliability and maintenance infrastructure may be limited. Its fetal and neonatal heart monitors are typically designed for ease of use, quick training, and durability, which is crucial in busy public maternity hospitals and smaller clinics.

    Looking ahead, BPL can benefit from increasing government investment in maternal and child health programs, which often include deployment of fetal monitoring systems to reduce perinatal mortality. Enhancing connectivity features, such as telemedicine-enabled fetal assessment and cloud-based data storage, would allow BPL to support regional referral networks and elevate its positioning from basic monitoring vendor to integrated perinatal technology partner in emerging markets.

14. Edan Instruments, Inc.:

    Edan Instruments, Inc. is a fast-growing Chinese medical device manufacturer with a strong presence in diagnostic ECG, ultrasound, and patient monitoring. In the fetal and neonatal heart monitor market, Edan offers a wide range of fetal monitors, cardiotocography systems, and neonatal monitors targeted at hospitals, maternity clinics, and community health centers. Its competitiveness stems from a balance of functionality, affordability, and increasingly sophisticated user interfaces.

    For 2025, Edan’s fetal and neonatal heart monitoring business is estimated to generate revenue of USD 90.00 million , corresponding to a market share of approximately 3.75% . This share indicates a strong presence in China and growing penetration in Latin America, Africa, and parts of Eastern Europe. Edan’s growth in this segment is often driven by government-backed hospital upgrade programs and private sector maternity clinic expansions.

    Edan differentiates itself through rapid product development cycles, localized software language support, and flexible configurations tailored to different care settings. Its fetal monitors typically feature clear graphical displays, automated trace analysis, and options for twin monitoring, which are important features in modern obstetric practice. On the neonatal side, Edan’s monitors integrate heart rate, SpO2, and other vital parameters, providing comprehensive surveillance for newborns in nurseries and NICUs.

    Strategically, Edan is well positioned to benefit from the global shift toward cost-effective, connected monitoring solutions. By investing in wireless connectivity, cloud-based data management, and integration with electronic medical records, Edan can move up the value chain and compete more directly with established multinationals. Its ability to adapt quickly to local regulatory requirements and clinical preferences will be a key driver of sustained growth within the global fetal and neonatal heart monitor market.

15. Monica Healthcare Ltd.:

    Monica Healthcare Ltd. is a highly specialized company focused on wearable and wireless fetal monitoring technologies. Its core products include patch-based fetal ECG and maternal ECG devices that enable ambulatory monitoring and improved mobility during labor. In the fetal and neonatal heart monitor market, Monica Healthcare is recognized as an innovation-driven challenger, particularly in the segment of non-invasive, wireless fetal heart monitoring.

    In 2025, Monica Healthcare’s revenue from fetal and neonatal heart monitoring is estimated at USD 30.00 million , which equates to a market share of roughly 1.25% . While this market share is relatively small, it reflects a focused presence in technologically advanced health systems and private maternity hospitals that are early adopters of wireless fetal monitoring. The company’s position is less about volume and more about shaping future standards in maternal mobility and comfort.

    Monica Healthcare’s competitive edge lies in its patented fetal ECG technology and wearable sensor form factors that reduce the need for traditional belts and wired transducers. This improves patient comfort, supports upright and mobile labor positions, and can facilitate remote or home-based fetal heart monitoring in selected clinical pathways. These capabilities align closely with evolving models of obstetric care, including midwife-led units and hybrid in-person/remote prenatal monitoring programs.

    Strategically, Monica Healthcare’s growth prospects are tied to broader adoption of telemedicine, digital maternity care pathways, and hospital initiatives to enhance patient experience. Collaborations with large monitoring or ultrasound companies, as well as integration of its fetal ECG data into enterprise perinatal systems, can expand its reach beyond early adopters. As the overall fetal and neonatal heart monitor market grows toward USD 3.87 Billion by 2032, Monica Healthcare’s innovative technology positions it as an attractive partner or acquisition target for larger players seeking differentiation in wireless and wearable fetal monitoring solutions.